Candriam S.C.A. Arcus Biosciences, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 20, 2021	SELL	$22.75 - $35.77 $9.3 Million - $14.6 Million	-408,991 Closed	0 $0
Q1 2021 Apr 29, 2021	SELL	$26.16 - $41.39 $392 - $620	-15 Reduced -0.0%	408,991 $10.2 Million
Q4 2020 Jan 22, 2021	SELL	$17.0 - $32.36 $1.35 Million - $2.58 Million	-79,664 Reduced 16.3%	409,006 $10.6 Million
Q3 2020 Oct 19, 2020	BUY	$17.14 - $25.47 $4.55 Million - $6.77 Million	265,728 Added 119.19%	488,670 $8.38 Million
Q2 2020 Jul 23, 2020	BUY	$13.97 - $36.56 $3.11 Million - $8.15 Million	222,942 New	222,942 $5.52 Million

201

51.6M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.